Welcome to our dedicated page for First Phosphate news (Ticker: PHOS), a resource for investors and traders seeking the latest updates and insights on First Phosphate stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect First Phosphate's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of First Phosphate's position in the market.
First Phosphate (NASDAQ: PHOS) announced that its American Depositary Receipts will be uplisted to the Nasdaq Global Market as a Level 2 ADR under ticker PHOS (CUSIP: 33611D301; ISIN: US33611D3017), effective at the opening of trading on August 10, 2026. The ADR ratio remains at ten common shares per one ADR.
From August 10, 2026, existing Level 1 ADRs will be delisted from OTCQX and automatically converted into Level 2 ADRs tradable on Nasdaq. The uplist does not affect the company’s common share listings on OTCQX (FRSPF), CSE (PHOS) and FSE (KD0). Holders can convert common shares into ADRs at no cost through BNY Mellon until December 31, 2026, and no new shares are issued or capital raised as part of this ADR upgrade.